Allosteric modulators of human A2B adenosine receptor.

[1]  E. Novellino,et al.  Modulation of A2B adenosine receptor by 1-Benzyl-3-ketoindole derivatives. , 2013, European journal of medicinal chemistry.

[2]  K. Jacobson,et al.  Allosteric modulation and functional selectivity of G protein-coupled receptors. , 2013, Drug discovery today. Technologies.

[3]  K. Ravid,et al.  Crosstalk between the equilibrative nucleoside transporter ENT2 and alveolar Adora2b adenosine receptors dampens acute lung injury , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  Xu-Feng Huang,et al.  Novel olanzapine analogues presenting a reduced H1 receptor affinity and retained 5HT2A/D2 binding affinity ratio , 2012, BMC pharmacology.

[5]  I. Modlin,et al.  Adenosine A2A and A2B receptor expression in neuroendocrine tumours: potential targets for therapy , 2012, Purinergic Signalling.

[6]  C. Borchers,et al.  Adora2b-elicited Per2 stabilization promotes a HIF-dependent metabolic switch critical for myocardial adaptation to ischemia , 2012, Nature Medicine.

[7]  E. Novellino,et al.  3-aryl-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-one: a novel template for the design of highly selective A₂B adenosine receptor antagonists. , 2012, Journal of medicinal chemistry.

[8]  J. Klawitter,et al.  Equilibrative nucleoside transporter 1 (ENT1) regulates postischemic blood flow during acute kidney injury in mice. , 2012, The Journal of clinical investigation.

[9]  H. Eltzschig,et al.  Neuronal guidance molecule netrin-1 attenuates inflammatory cell trafficking during acute experimental colitis , 2011, Gut.

[10]  A. IJzerman,et al.  Allosteric modulation of adenosine receptors. , 2011, Biochimica et biophysica acta.

[11]  Kenneth A Jacobson,et al.  Recent developments in adenosine receptor ligands and their potential as novel drugs. , 2011, Biochimica et biophysica acta.

[12]  M. Loza,et al.  Discovery of LAS101057: A Potent, Selective, and Orally Efficacious A2B Adenosine Receptor Antagonist. , 2011, ACS medicinal chemistry letters.

[13]  B. Fredholm,et al.  International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors—An Update , 2011, Pharmacological Reviews.

[14]  P. Sexton,et al.  Allosteric modulation of G protein-coupled receptors: A pharmacological perspective , 2011, Neuropharmacology.

[15]  F. Da Settimo,et al.  Allosteric modulators for adenosine receptors: an alternative to the orthosteric ligands. , 2010, Current topics in medicinal chemistry.

[16]  F. Musumeci,et al.  A1 Receptors Ligands: Past, Present and Future Trends , 2010 .

[17]  J. Schwab,et al.  Hypoxia-inducible factor–dependent induction of netrin-1 dampens inflammation caused by hypoxia , 2009, Nature Immunology.

[18]  Adriaan P IJzerman,et al.  Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models , 2009, BMC pharmacology.

[19]  T. Eckle,et al.  A2B adenosine receptor signaling attenuates acute lung injury by enhancing alveolar fluid clearance in mice. , 2008, The Journal of clinical investigation.

[20]  D. Carbone,et al.  Host A(2B) adenosine receptors promote carcinoma growth. , 2008, Neoplasia.

[21]  J. Zablocki,et al.  Progress in the discovery of selective, high affinity A2B adenosine receptor antagonists as clinical candidates , 2008, Purinergic Signalling.

[22]  S. Srinivasan,et al.  Blockade of adenosine A2B receptors ameliorates murine colitis , 2008, British journal of pharmacology.

[23]  P. Baraldi,et al.  Recent improvements in the development of A2B adenosine receptor agonists , 2008, Purinergic Signalling.

[24]  David A. Lustig,et al.  Discovery of a novel A2B adenosine receptor antagonist as a clinical candidate for chronic inflammatory airway diseases. , 2008, Journal of medicinal chemistry.

[25]  C. Ledent,et al.  Cardioprotection by Ecto-5′-Nucleotidase (CD73) and A2B Adenosine Receptors , 2007, Circulation.

[26]  E. Elzein,et al.  A2B adenosine receptor antagonists and their potential indications , 2006 .

[27]  J. Baeyens,et al.  Differences in the allosteric modulation by phenytoin of the binding properties of the σ1 ligands [3H](+)‐pentazocine and [3H]NE‐100 , 2006, Synapse.

[28]  T. Ziegler,et al.  TNF-α upregulates adenosine 2b (A2b) receptor expression and signaling in intestinal epithelial cells: a basis for A2bR overexpression in colitis , 2005, Cellular and Molecular Life Sciences.

[29]  A. Christopoulos,et al.  Allosteric Modulation of the Cannabinoid CB1 Receptor , 2005, Molecular Pharmacology.

[30]  K. Klotz,et al.  Human breast cancer cell line MDA‐MB‐231 expresses endogenous A2B adenosine receptors mediating a Ca2+ signal , 2005, British journal of pharmacology.

[31]  C. Allen.  Bioscience industry in metro Atlanta. , 2005, Drug discovery today.

[32]  I. Biaggioni,et al.  Hypoxia Modulates Adenosine Receptors in Human Endothelial and Smooth Muscle Cells Toward an A2B Angiogenic Phenotype , 2004, Hypertension.

[33]  Ettore Novellino,et al.  A1 adenosine receptor antagonists, 3‐aryl[1,2,4]triazino[4,3‐a]benzimidazol‐4‐(10H)‐ones (ATBIs) and N‐alkyl and N‐acyl‐(7‐substituted‐2‐phenylimidazo[1,2‐a][1,3,5]triazin‐4‐yl)amines (ITAs): Different recognition of bovine and human binding sites , 2004 .

[34]  J. Traynor,et al.  The [35S]GTPγS binding assay: approaches and applications in pharmacology , 2003 .

[35]  S. Moro,et al.  Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as adenosine receptor antagonists. Influence of the N5 substituent on the affinity at the human A 3 and A 2B adenosine receptor subtypes: a molecular modeling investigation. , 2003, Journal of medicinal chemistry.

[36]  B. Fredholm,et al.  Signalling from adenosine receptors to mitogen-activated protein kinases. , 2003, Cellular signalling.

[37]  I. Biaggioni,et al.  Mast Cell–Mediated Stimulation of Angiogenesis: Cooperative Interaction Between A2B and A3 Adenosine Receptors , 2003, Circulation research.

[38]  P. Magistretti,et al.  A2B receptor activation promotes glycogen synthesis in astrocytes through modulation of gene expression. , 2003, American journal of physiology. Cell physiology.

[39]  T. Kenakin,et al.  G Protein-Coupled Receptor Allosterism and Complexing , 2002, Pharmacological Reviews.

[40]  B. Fredholm,et al.  International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. , 2001, Pharmacological reviews.

[41]  S. Urwyler,et al.  Positive allosteric modulation of native and recombinant gamma-aminobutyric acid(B) receptors by 2,6-Di-tert-butyl-4-(3-hydroxy-2,2-dimethyl-propyl)-phenol (CGP7930) and its aldehyde analog CGP13501. , 2001, Molecular pharmacology.

[42]  K. Jacobson,et al.  [3H]MRS 1754, a selective antagonist radioligand for A(2B) adenosine receptors. , 2001, Biochemical pharmacology.

[43]  B. Fredholm,et al.  Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. , 2001, Biochemical pharmacology.

[44]  A. IJzerman,et al.  Why are A(2B) receptors low-affinity adenosine receptors? Mutation of Asn273 to Tyr increases affinity of human A(2B) receptor for 2-(1-Hexynyl)adenosine. , 2000, Molecular pharmacology.

[45]  K. Jacobson,et al.  Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A(2B) adenosine receptors. , 2000, Journal of medicinal chemistry.

[46]  B. Fredholm,et al.  Comparative pharmacology of human adenosine receptor subtypes – characterization of stably transfected receptors in CHO cells , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

[47]  I Biaggioni,et al.  Adenosine A2B receptors. , 1997, Pharmacological reviews.

[48]  B. Fredholm,et al.  A modification of a protein-binding method for rapid quantification of cAMP in cell-culture supernatants and body fluid. , 1990, Analytical biochemistry.

[49]  P. Baraldi,et al.  Recent developments in A2B adenosine receptor ligands. , 2009, Handbook of experimental pharmacology.

[50]  Arthur Christopoulos,et al.  Allosteric modulation of G protein-coupled receptors. , 2007, Annual review of pharmacology and toxicology.

[51]  F. Ciruela,et al.  Adenosine A2B receptors behave as an alternative anchoring protein for cell surface adenosine deaminase in lymphocytes and cultured cells. , 2001, Molecular pharmacology.